Thomas Bachelot

Summary

Publications

  1. pmc Comparative efficacy of everolimus plus exemestane versus fulvestrant for hormone-receptor-positive advanced breast cancer following progression/recurrence after endocrine therapy: a network meta-analysis
    Thomas Bachelot
    Departement de cancerologie medicale, Centre Leon Berard, 28 rue Laennec, 69008, Lyon Cedex 08, France
    Breast Cancer Res Treat 143:125-33. 2014
  2. doi request reprint Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study
    Thomas Bachelot
    Département de Cancérologie Médicale et Unité INSERM U590, Centre Leon Berard, 28 rue Laennec, 69373 Lyon Cedex 08, France
    J Clin Oncol 30:2718-24. 2012
  3. doi request reprint Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study
    Thomas Bachelot
    Department of Medical Oncology and Léon Bérard Centre, Lyon, France
    Lancet Oncol 14:64-71. 2013
  4. doi request reprint Chemotherapy for metastatic breast cancer. Comparison of clinical practice and cost of drugs in two cohorts of patients: 1994-1998 and 2003-2006
    Guillaume Galy
    Department of Pharmacy, Centre Leon Berard, Lyon, 69008, France
    Breast Cancer Res Treat 128:187-95. 2011
  5. doi request reprint Use of the monoclonal antibody anti-HER2 trastuzumab in the treatment of metastatic breast cancer: a cost-effectiveness analysis
    Bénédicte Poncet
    Département d information médicale, Unit of Medico Economic Evaluation, Hospices Civils de Lyon, Lyon, France
    Am J Clin Oncol 31:363-8. 2008
  6. doi request reprint CD4 lymphopenia to identify end-of-life metastatic cancer patients
    Julien Peron
    Universite de Lyon, Lyon, France Université Lyon 1, Villeurbanne, France
    Eur J Cancer 49:1080-9. 2013
  7. doi request reprint Bevacizumab and paclitaxel for breast cancer patients with central nervous system metastases: a case series
    Sana Intidhar Labidi
    Department of Medical Oncology, Centre Leon Berard, Laennec, France
    Clin Breast Cancer 9:118-21. 2009
  8. doi request reprint A phase 2 trial of whole-brain radiotherapy combined with intravenous chemotherapy in patients with brain metastases from breast cancer
    Philippe A Cassier
    Multidisciplinary Medical Oncology Day Unit, Edouard Herriot Hospital, Lyon, France
    Cancer 113:2532-8. 2008
  9. doi request reprint Patients with metastatic breast cancer leading to CD4+ T cell lymphopaenia have poor outcome
    Olivier Tredan
    Department of Medical Oncology, Centre Leon Berard, 28 rue Laennec, Lyon 69008, France
    Eur J Cancer 49:1673-82. 2013
  10. doi request reprint [Systemic treatment of brain metastases from breast cancer: cytotoxic chemotherapy and targeted therapies]
    Thomas Bachelot
    Centre Leon Berard, Oncologie Médicale, 69008 Lyon, France
    Bull Cancer 100:7-14. 2013

Detail Information

Publications42

  1. pmc Comparative efficacy of everolimus plus exemestane versus fulvestrant for hormone-receptor-positive advanced breast cancer following progression/recurrence after endocrine therapy: a network meta-analysis
    Thomas Bachelot
    Departement de cancerologie medicale, Centre Leon Berard, 28 rue Laennec, 69008, Lyon Cedex 08, France
    Breast Cancer Res Treat 143:125-33. 2014
    ..These results suggest that everolimus plus exemestane may be more efficacious than fulvestrant in patients with advanced breast cancer who progress on or after adjuvant or first-line therapy with a nonsteroidal aromatase inhibitor. ..
  2. doi request reprint Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study
    Thomas Bachelot
    Département de Cancérologie Médicale et Unité INSERM U590, Centre Leon Berard, 28 rue Laennec, 69373 Lyon Cedex 08, France
    J Clin Oncol 30:2718-24. 2012
    ..This analysis evaluated efficacy and safety of everolimus in combination with tamoxifen in patients with mBC resistant to aromatase inhibitors (AIs)...
  3. doi request reprint Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study
    Thomas Bachelot
    Department of Medical Oncology and Léon Bérard Centre, Lyon, France
    Lancet Oncol 14:64-71. 2013
    ..Few systemic options are available. We aimed to investigate the combination of lapatinib plus capecitabine for the treatment of previously untreated brain metastases from HER2-positive breast cancer...
  4. doi request reprint Chemotherapy for metastatic breast cancer. Comparison of clinical practice and cost of drugs in two cohorts of patients: 1994-1998 and 2003-2006
    Guillaume Galy
    Department of Pharmacy, Centre Leon Berard, Lyon, 69008, France
    Breast Cancer Res Treat 128:187-95. 2011
    ..56; P = 0.0002). New chemotherapeutic agents induced a significant cost increase over time. The limited size and heterogeneity of our cohort do not allow any conclusion concerning their impact on survival...
  5. doi request reprint Use of the monoclonal antibody anti-HER2 trastuzumab in the treatment of metastatic breast cancer: a cost-effectiveness analysis
    Bénédicte Poncet
    Département d information médicale, Unit of Medico Economic Evaluation, Hospices Civils de Lyon, Lyon, France
    Am J Clin Oncol 31:363-8. 2008
    ..This open controlled prospective study aimed at evaluating the medical and economical impact of first line chemotherapy for metastatic breast cancer (MBC)...
  6. doi request reprint CD4 lymphopenia to identify end-of-life metastatic cancer patients
    Julien Peron
    Universite de Lyon, Lyon, France Université Lyon 1, Villeurbanne, France
    Eur J Cancer 49:1080-9. 2013
    ..Cancer patients with CD4 lymphopenia have an increased risk of severe toxicity after administration of cytotoxic chemotherapy. The impact of CD4 lymphopenia on long term overall survival (OS) of cancer patients was explored in this work...
  7. doi request reprint Bevacizumab and paclitaxel for breast cancer patients with central nervous system metastases: a case series
    Sana Intidhar Labidi
    Department of Medical Oncology, Centre Leon Berard, Laennec, France
    Clin Breast Cancer 9:118-21. 2009
    ....
  8. doi request reprint A phase 2 trial of whole-brain radiotherapy combined with intravenous chemotherapy in patients with brain metastases from breast cancer
    Philippe A Cassier
    Multidisciplinary Medical Oncology Day Unit, Edouard Herriot Hospital, Lyon, France
    Cancer 113:2532-8. 2008
    ..A study was conducted to determine the efficacy, tolerability, and safety of concurrent cisplatin and vinorelbine chemotherapy and radiotherapy in patients with previously untreated brain metastases from breast cancer...
  9. doi request reprint Patients with metastatic breast cancer leading to CD4+ T cell lymphopaenia have poor outcome
    Olivier Tredan
    Department of Medical Oncology, Centre Leon Berard, 28 rue Laennec, Lyon 69008, France
    Eur J Cancer 49:1673-82. 2013
    ..Low lymphocyte count is a prognostic factor in cancer patients including metastatic breast cancer patients (MBC) but the relative role of each lymphocyte subtype is unclear in MBC...
  10. doi request reprint [Systemic treatment of brain metastases from breast cancer: cytotoxic chemotherapy and targeted therapies]
    Thomas Bachelot
    Centre Leon Berard, Oncologie Médicale, 69008 Lyon, France
    Bull Cancer 100:7-14. 2013
    ..Promoting novel targeted approaches and innovative therapeutic combinations is a critical need to improve survival of breast cancer patients with brain metastases...
  11. pmc Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas
    Isabelle Ray-Coquard
    Université de Lyon Centre Léon Bérard, Department of Medical Oncology and EA SIS 4128, Lyon, France
    Cancer Res 69:5383-91. 2009
    ..48; 95% CI, 1.03-2.1) along with IPI. Our findings show that lymphopenia is an independent prognostic factor for overall and progression-free survival in several cancers...
  12. doi request reprint Breast cancer-derived transforming growth factor-β and tumor necrosis factor-α compromise interferon-α production by tumor-associated plasmacytoid dendritic cells
    Vanja Sisirak
    Universite de Lyon, Lyon, France
    Int J Cancer 133:771-8. 2013
    ..Our findings indicate that targeting TApDC to restore their IFN-α production might be an achievable strategy to induce antitumor immunity in breast cancer by combining TLR7/9-based immunotherapy with TGF-β and TNF-α antagonists...
  13. pmc Validation of prognostic scores for survival in cancer patients beyond first-line therapy
    Olivier Tredan
    Universite de Lyon, Centre Leon Berard, Department of Medical Oncology, 28 rue Laennec, 69008 Lyon, France
    BMC Cancer 11:95. 2011
    ..We aimed to validate prognostic scores for survival in patients undergoing chemotherapy for advanced or metastatic cancer after first-line treatment...
  14. pmc Prognostic value of the expression of C-Chemokine Receptor 6 and 7 and their ligands in non-metastatic breast cancer
    Philippe A Cassier
    Department of Medecine, Centre Leon Berard, Lyon, France
    BMC Cancer 11:213. 2011
    ..Chemokines CCL19, CCL20 and CCL21 and their receptors CCR6 and CCR7, were assessed as potential biomarkers of metastatic dissemination in primary breast cancer...
  15. doi request reprint First-line endocrine therapy alone could be a reasonable treatment option for hormone-positive, HER2-positive metastatic breast cancer
    Julien Peron
    Centre Leon Berard, Department of Medical Oncology, 28, rue Laennec, 69008 Lyon, France
    Bull Cancer 99:E18-25. 2012
    ..Previously validated clinical practice guidelines recommending the use of endocrine therapy alone in first line might be changed...
  16. doi request reprint Impaired IFN-α production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression
    Vanja Sisirak
    Universite de Lyon, Lyon, France
    Cancer Res 72:5188-97. 2012
    ..Thus, targeting pDC to restore their IFN-α production may represent an attractive therapeutic strategy to overcome immune tolerance in breast cancer...
  17. doi request reprint Paclitaxel is effective in relapsed head and neck squamous cell carcinoma: a retrospective study of 66 patients at a single institution
    Jerome Fayette
    Universite de Lyon, Centre Leon Berard, Lyon, France
    Anticancer Drugs 21:553-8. 2010
    ..2 months (95% CI: 5.2-8.8). Paclitaxel can be used in symptomatic patients. Although no improvement of overall survival can be expected, paclitaxel treatment is safe and achieves interesting response rates...
  18. doi request reprint Multidisciplinarity and medical decision, impact for patients with cancer: sociological assessment of two tumour committees' organization
    Patrick Castel
    Centre Leon Berard, Lyon, France
    Bull Cancer 99:E34-42. 2012
    ..In the present study, we evaluated the organization of two multidisciplinary committees, one for breast cancer and one for sarcoma, in a French Comprehensive Cancer Centre...
  19. doi request reprint [Antihormonal therapy in breast cancer and mTOR inhibitors]
    Pierre Etienne Heudel
    Centre Leon Berard, Oncologie Médicale, Lyon, France
    Bull Cancer 98:1431-7. 2011
    ....
  20. doi request reprint [Adjuvant treatments in breast cancer: interest of completion of axillary dissection in case of micrometastases or isolated tumor cells in sentinel lymph node]
    Caroline Schmitt
    Centre Leon Berard, 28, Lyon, France
    Bull Cancer 99:463-9. 2012
    ..The results of our study show that non-sentinel lymph node status modify systemic therapy for a very few patients (less than 4% concerning chimiotherapy and less than 15% concerning radiotherapy)...
  21. ncbi request reprint A serum nuclear magnetic resonance-based metabolomic signature of advanced metastatic human breast cancer
    Elodie Jobard
    Universite de Lyon, CNRS ENS Lyon UCB Lyon 1, Institut des Sciences Analytiques, Centre de RMN a Tres Hauts Champs, 5 rue de la Doua, 69100 Villeurbanne, France Université de Lyon, Centre Leon Berard, Departement d Oncologie Medicale, 28 rue Laennec, 69008 Lyon, France
    Cancer Lett 343:33-41. 2014
    ..This work illustrates the strong potential of NMR metabolic phenotyping for the diagnosis, prognosis, and management of cancer patients...
  22. ncbi request reprint [Neoadjuvant chemotherapy and ovarian cancer]
    Isabelle Ray-Coquard
    Centre Leon Berard, Lyon
    Bull Cancer 93:669-76. 2006
    ..The strategy of neoadjuvant chemotherapy, followed by interval debulking surgery, should be confirmed in a prospective randomized trial. The EORTC55971 trial is currently addressing this issue...
  23. ncbi request reprint [Angiogenesis and breast cancer]
    Thomas Bachelot
    Centre Leon Berard, Departement de Medecine, 28, rue Laennec, 69373 Lyon Cedex 08
    Bull Cancer 94:S203-10. 2007
    ..This is a review of the major biological and clinical data available on the critical role of angiogenesis in breast cancer. We will also review the different clinical studies reported to date in this area...
  24. pmc Can treatment with Cocculine improve the control of chemotherapy-induced emesis in early breast cancer patients? A randomized, multi-centered, double-blind, placebo-controlled Phase III trial
    David Perol
    Centre Leon Berard, 28 rue Laennec, Lyon Cedex 08, 69373, France
    BMC Cancer 12:603. 2012
    ....
  25. doi request reprint Molecular characterization of anastrozole resistance in breast cancer: pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibitor
    Paul Vilquin
    ISPB, Faculte de Pharmacie, Universite Lyon 1, Lyon, France
    Int J Cancer 133:1589-602. 2013
    ....
  26. pmc Netrin-1 expression confers a selective advantage for tumor cell survival in metastatic breast cancer
    Julien Fitamant
    Apoptosis, Cancer, and Development Laboratory Equipe Labellisée La Ligue, Centre National de la Recherche Scientifique, Unite Mixte de Recherche 5238, Centre Leon Berard, Université de Lyon 69008 Lyon, France
    Proc Natl Acad Sci U S A 105:4850-5. 2008
    ....
  27. ncbi request reprint Lymphopenia: a new independent prognostic factor for survival in patients treated with whole brain radiotherapy for brain metastases from breast carcinoma
    Line Claude
    Department of Radiation Oncology, Hopital Edouard Herriot, Lyon, France
    Radiother Oncol 76:334-9. 2005
    ..To determine overall survival (OS) and independent prognostic factors in patients with brain metastases (BM) from breast cancer treated by whole brain radiotherapy (WBR)...
  28. doi request reprint Early detection of tumor cells by innate immune cells leads to T(reg) recruitment through CCL22 production by tumor cells
    Julien Faget
    Centre Leon Berard, F 69000 Lyon, France
    Cancer Res 71:6143-52. 2011
    ....
  29. doi request reprint Body weight change in women receiving adjuvant chemotherapy for breast cancer: a French prospective study
    Olivier Tredan
    Université de Lyon Centre Léon Bérard, Department of Medical Oncology, 28 rue Laennec, 69008 Lyon, France
    Clin Nutr 29:187-91. 2010
    ..Adjuvant chemotherapy has frequently been associated with weight gain after breast cancer diagnosis. We aimed to prospectively evaluate body weight variations in French patients with early breast cancer...
  30. pmc Factors of interrupting chemotherapy in patients with Advanced Non-Small-Cell Lung Cancer
    Rhizlane Belbaraka
    Department of Medical Oncology, Centre Leon Berard, 28 rue Laennec, Lyon 69008, France
    BMC Res Notes 3:164. 2010
    ..In this prospective study, which included 45 patients, we identified clinical and biological variables as outcome predictors in metastatic Non-Small Cell lung cancer after first line chemotherapy were identified...
  31. ncbi request reprint A phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study
    Philippe A Cassier
    Medical Oncology, Hopital Edouard Herriot, Université de Lyon et Hospices Civils de Lyon, Lyon, France
    Breast Cancer Res Treat 109:343-50. 2008
    ..In first-line metastatic breast cancer, both paclitaxel (P)-doxorubicin (A) and docetaxel (D)-doxorubicin (A) combinations have shown superiority over treatments without taxane. The aim of this study was to compare the two combinations...
  32. doi request reprint Oral moxifloxacin or intravenous ceftriaxone for the treatment of low-risk neutropenic fever in cancer patients suitable for early hospital discharge
    Catherine Sebban
    Centre Leon Berard, 28 rue Laennec, Lyon, France
    Support Care Cancer 16:1017-23. 2008
    ..Optimal management remains to be clearly defined, and new oral antibiotics need to be evaluated in this setting...
  33. ncbi request reprint Cost-effectiveness analysis of strategies for HER2 testing of breast cancer patients in France
    Magali Morelle
    Health Economics Research Group in Oncology, Centre Leon Berard, Lyon, France
    Int J Technol Assess Health Care 22:396-401. 2006
    ..A cost-effectiveness analysis was conducted comparing diagnostic strategies for determining the HER2 status of invasive breast carcinomas, as an indication for trastuzumab at metastatic relapse...
  34. ncbi request reprint High incidence of mammary intraepithelial neoplasia development in Men1-disrupted murine mammary glands
    Christelle Seigne
    Universite Lyon, F 69000, Lyon, France
    J Pathol 229:546-58. 2013
    ..Taken together, the current work indicates a role of Men1 inactivation in the development of mammary pre-cancerous lesions in mice and a potential role in human mammary cancer...
  35. ncbi request reprint [Prognostic factors for febrile neutropenia]
    Isabelle Ray-Coquard
    Centre Leon Berard, 28, rue Laennec, 69008 Lyon, France
    Bull Cancer 93:501-6. 2006
    ..Research in quantifying the risk of neutropenic complications may make it possible in the near future to target patients at greater risk with appropriate preventive strategies, thereby maximizing the benefits and minimizing the costs...
  36. ncbi request reprint IL-6 as an intracrine growth factor for renal carcinoma cell lines
    Laurent Alberti
    Equipe Cytokine et Cancer, Unité Inserm 590, Lyon, France
    Int J Cancer 111:653-61. 2004
    ..IL-6 ASON inhibited the proliferation of the 8 RCC cell lines tested additively with IL-4 or IL-13. IL-6 is an intracrine growth factor in renal cell carcinoma cell lines...
  37. ncbi request reprint Breast carcinoma cells promote the differentiation of CD34+ progenitors towards 2 different subpopulations of dendritic cells with CD1a(high)CD86(-)Langerin- and CD1a(+)CD86(+)Langerin+ phenotypes
    Marie Cécile Thomachot
    Equipe Cytokines et Cancers, INSERM U 590, Centre Léon B, Lyon, France
    Int J Cancer 110:710-20. 2004
    ..The infiltration of BCC by these altered DC may contribute to the impaired immune response against the tumor...
  38. ncbi request reprint Epirubicin and paclitaxel (EPI-TAX regimen) for advanced ovarian cancer after failure of platinum-containing regimens
    Isabelle Ray-Coquard
    Centre Leon Berard, 28, rue Laennec, 69008, Lyon, France
    Gynecol Oncol 88:351-7. 2003
    ..We have assessed the feasibility and evaluated the tolerance of epirubicin (EPI) combined with paclitaxel (TAX) in heavily pretreated ovarian cancer patients...
  39. ncbi request reprint [Adjuvant therapy for breast cancer patients: treatment decision tree from a French cancer network]
    Thomas Bachelot
    Centre Leon Berard, 28, rue Laennec, 69373 Lyon Cedex 08, France
    Bull Cancer 89:897-903. 2002
    ..However, due to the subjectivity of risk/benefit estimations, patients themselves should become more involved in the decision-making process...
  40. doi request reprint Mutational characterization of individual breast tumors: TP53 and PI3K pathway genes are frequently and distinctively mutated in different subtypes
    Sandrine Boyault
    Laboratoire de Recherche Translationnelle, Centre Leon Berard, 28 rue Laennec, 69373 Lyon Cedex 08, France
    Breast Cancer Res Treat 132:29-39. 2012
    ..These two distinct mutation patterns were significantly associated to hormone receptor expression but independent of HER2 status...
  41. pmc Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II study
    Thomas Bachelot
    EORTC, Soft Tissue and Bone Sarcoma Group, Centre Léon Bérard and Université Claude Bernard, Lyon, France
    BMC Cancer 14:166. 2014
    ..This phase II study evaluated the efficacy and safety/tolerability of sunitinib plus trastuzumab in patients with HER2-positive advanced breast cancer (ABC)...
  42. ncbi request reprint The role of angiogenesis in endocrine liver metastases: an experimental study
    Celine Pourreyron
    INSERM, U865, Faculte Laennec, Universite Claude Bernard Lyon 1, Lyon, France
    J Surg Res 144:64-73. 2008
    ..4 +/- 5.6% versus 18.3 +/- 3.4). Our results suggest that active angiogenesis is not necessary for the engraftment and early growth of endocrine cells metastatic to the liver but is required at a later stage of progression...